Modulateur d'interaction protéine-protéine

Autophagy inhibitor that selectively targets the StART domain of GRAMD1A

BT13 is a GFL mimetic and a potent and selective activator of RET tyrosine kinase and its downstream signaling cascades. BT13 promoted neurite outgrowth from dorsal root ganglia sensory neurons, alleviated mechanical hypersensitivity and reversed injury-induced changes in dorsal root ganglia neurons in experimental animals with the spinal nerve ligation-induced neuropathy.

Tubulin ligand which promotes microtubule assembly and stabilises microtubule cytoskeleton against depolymerisation. The compound has anti-tumoral activity since its interference with cytoskeleton dynamics affects the assembly of mitotic spindle, segregation of chromosomes, cell division and blocks the cell cycle in G1 or M phase. The compound is also used for the purification of tubulin or microtubule-associated proteins.

Microtubule disrupter; anti-mitotic drug; anti-cancer alkaloid

Inhibitor of BET bromodomain; antineoplastic

Inhibitor of Hsp90 chaperone protein; anti-neoplastic

Microtubule stabilizer; natural polyketide compound; antineoplastic

Inhibits N-Acetyl-mediated interaction between BE2M (E2 conjugating enzyme) and DCN1 (a component of E3 ligase complex). Also has inhibitory action on DCN2 and NEDD8 ubiquitin-like protein. Reduces anchorage-independent growth in DCN1-amplified cell line.

Microtubule-stabilizing agent; antineoplastic;

A calcium-binding protein S100A9 inhibitor with immunomodulatory activity that reduces pathology in experimental collagenase-induced osteoarthritis.

Inhibits actin polymerization

Inhibits RGS proteins, selective for RGS4

Oxaliplatin is a platinum-based DNA-cross-linking agent. It is a chemotherapeutic drug, often used in combination with leucovorin, fluorouracil, and capecitabine. Oxaliplatin works by cross-linking DNA thus inhibiting the synthesis of RNA and proteins, which leads to cell death and inhibition of cancer cells growth. It is more effective than cisplatin or irinotecan in treating metastatic cancer. Oxaliplatin also has effects on Toll-like receptor 4 (TLR4) expression levels in vitro and in vivo models. In addition, oxaliplatin's effect on ATP binding cassette transporter proteins may be responsible for its antitumour activity against solid tumours. Oxaliplatin is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

A chemical probe for the dual bromodomains of human transcription-initiation-factor TFIID subunit 1 (TAF1). GNE 371 binds TAF1 with an IC50 of 10 nM and is selective over other bromodomain family members. Exerts anti-proliferative effects in synergy with BET inhibitor JQ1.

Recombinant protein against VEGF(A); binds placental growth factor (PIGF)

Dual PI3K/mTOR inhibitor

Formyl peptide receptor-1 (FPR-1) antagonist

VS1 is a novel synthetic peptide, which is engineered to function as an antimicrobial agent. This peptide originates from recombinant DNA technology, providing a customizable approach to target specific microbial strains. Its mode of action involves the selective disruption of microbial cell membranes, leading to the lysis and consequent death of the target cell. The specificity of VS1 for microbial cells over mammalian cells minimizes off-target effects, making it a highly effective agent for infection control. The applications of VS1 are diverse within the scientific and medical communities. It is particularly useful in the study of microbial resistance, offering insights into the development of new antimicrobial therapies. VS1 has potential applications in clinical settings for treating infections resistant to traditional antibiotics. Researchers harness VS1 in laboratory experiments aimed at understanding microbial physiology and in developing new methods for microbial detection. Overall, VS1 serves as an invaluable tool for advancing the field of microbiology and infectious disease research, providing novel solutions to combat persistent and resistant microbial infections.

Iguratimod is a drug that is used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis. This drug works by suppressing the activity of inflammatory cells and cytokines such as interleukin-1 and tumor necrosis factor-alpha (TNF-alpha). By reducing the levels of these cytokines, Iguratimod helps to alleviate inflammation and joint damage associated with conditions like rheumatoid arthritis. Iguratimod is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Levosimendan has been shown to act as a calcium sensitiser and increase cytosolic Ca2+ levels. It is an analog of the cardiac glycoside, ouabain. This drug has been shown to be effective for the treatment of congestive heart failure and is used to increase the heart’s contractility and decrease its rate in patients who have low cardiac output. Levosimendan also causes vasodilation by increasing nitric oxide production in vascular endothelial cells. Levosimendan is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.